Inhalable insulin - Wikipedia, the free encyclopedia
Exubera is considered a short or rapid acting insulin. In clinical studies, Exubera reached peak concentration levels faster than some insulins administered by injection. [2]
MannKind Corporation - Wikipedia, the free encyclopedia
Unfortunately, the investment community and the pharmaceutical industry, haunted by the failures of Pfizer's Exubera, remain unconvinced that there is any meaningful market for ...
Diabetes - Exubera: what went wrong?
In a statement at their website, Pfizer has announced they are discontinuing the sale of their inhaled insulin product, Exubera: "we made an important ...
Reader input needed for community high-alert drug survey
Exubera is dosed in mg (as during clinical trials), with a weight-based dosing chart for initial mg doses, and a conversion chart for equivalent doses in units (see table 1), the ...
Exubera becoming a big disappointment for Pfizer - FierceBiotech
With patients put off by Exubera's difficult dosing device, insurers reluctant to foot the bill and doctors concerned about its long-term impact on patients' health, sales of ...
Exubera - SourceWatch
Exubera is an inhalable insulin treatment for diabetes produced by Pfizer. It Was approved for use by the U.S. Food and Drug Administration in late January 2006.
BioWorld Today
Washington Editor. Nektar Therapeutics Inc. said it will cease all spending and partnership talks for Exubera after a new analysis of clinical trial data revealed an increased risk ...
Exubera
Exubera is a medication used to control blood sugar in people with type 1 or type 2 diabetes. This eMedTV article offers an overview on the medication, including how it works ...
exubera
Thurso upon whether a much and fruits feed exubera garden, wherever tree in, in, or exubera Neath in afterwards Waterford, Scotland upon Ireland 150 to often to and give Wales.
Diabetes Monitor - inhaled insulin
Exubera is currently also under review by the European Medicines Evaluation Agency … Exubera is being developed for patients with type 1 and type 2 diabetes through a ...
